metaEvidence - overview


			Statistically conclusive or suggested result	Inconclusive results	Uncertain results	Safety results
la/mBC - HR-positive - 2nd line (L2) breast cancer - HR positive la/mBC - HR positive la/mBC - HR-positive - 2nd line (L2)
versus exemestane
	entinostat plus exemestane vs. exemestane	2	none	inconclusive results for: deaths (OS); progression or deaths (PFS); objective responses (ORR)	-	-
	tucidinostat plus exemestane vs. exemestane	1	none	inconclusive results for: DOR	statistically conclusive 25 % decrease in progression or deaths (PFS) but the degree if certainty is unassessable suggested 59 % increase in CBR but the degree if certainty is unassessable suggested 2.3-fold increase in objective responses (ORR) but the degree if certainty is unassessable	-
la/mBC - HR positive - L2 - all population breast cancer - HR positive la/mBC - HR positive la/mBC - HR-positive - 2nd line (L2) la/mBC - HR positive - L2 - all population
la/mBC - HR positive - L2 - PIK3CA mutant breast cancer - HR positive la/mBC - HR positive la/mBC - HR-positive - 2nd line (L2) la/mBC - HR positive - L2 - PIK3CA mutant